世界の血栓症治療薬市場 – 業界動向と2031年までの予測

血栓症治療薬市場の分析と規模

血栓症治療薬市場は、革新的な抗凝固薬や血栓溶解薬の登場により急速に発展しています。新薬発見のための AI や個別化医療などの最新技術により、治療効果が向上しています。血栓症に対する意識の高まり、研究開発投資の増加、血栓性疾患の蔓延により、市場は成長しています。洞察により、より安全で効果的な治療法への傾向が明らかになっています。                                

世界の血栓症治療薬市場規模は、2023年に112億4,000万米ドルと評価され、2024年から2031年の予測期間中に8.59%のCAGRで成長し、2031年までに217億3,000万米ドルに達すると予測されています。これは、市場価値を示しています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、データブリッジマーケットリサーチがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

レポートの範囲と市場セグメンテーション

Market Definition

A thrombosis drug, also known as an anticoagulant or blood thinner, is a medication that prevents blood clots (thrombosis) from forming or growing. These drugs include warfarin, heparin, and newer agents such as rivaroxaban and apixaban. They are used to treat or prevent conditions such as deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation patients.            

Thrombosis Drug Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases, such as heart attacks and strokes, which often lead to thrombosis, drives the thrombosis drug market. For instance, the American Heart Association reports an increasing number of stroke cases each year, necessitating the development and use of effective thrombosis treatments. This growing demand for preventative and therapeutic drugs significantly boosts market growth, as more patients require ongoing management of their conditions.

• Increasing Obesity Rates

Increasing obesity rates significantly drive the thrombosis drug market, as obesity is a major risk factor for thrombosis. For instance, the Centers for Disease Control and Prevention (CDC) reports a consistent rise in obesity rates in the U.S., with over 40% of adults classified as obese in recent years. This growing population at risk elevates the demand for effective thrombosis treatments, thereby expanding the market.

Opportunities

• Enhanced Diagnostic Techniques

Improved diagnostic techniques for thrombosis, such as ultrasound imaging and D-dimer testing, facilitate early and precise detection of blood clots. For instance, advanced imaging modalities such as CT angiography allow clinicians to identify thrombosis in pulmonary arteries swiftly. This early diagnosis not only ensures prompt initiation of thrombosis treatment but also boosts the demand for effective drugs. Consequently, healthcare providers and patients benefit from improved outcomes, driving growth in the thrombosis drug market.

• Aging Population Create Demand

The aging global population significantly drives the thrombosis drug market. As people age, the risk of developing thrombosis rises due to factors such as decreased mobility and higher prevalence of conditions such as atrial fibrillation. For instance, in countries such as Japan and Italy, where a substantial portion of the population is elderly, the demand for effective thrombosis treatments has surged, bolstering market growth and encouraging pharmaceutical advancements.

Restraints/Challenges

• Ethical and Legal Considerations in Genetic Testing

Ethical and legal concerns regarding genetic testing and personalized medicine create uncertainty, deterring both individuals and healthcare providers from embracing these diagnostic approaches. This hesitation limits market growth for autoimmune disease diagnosis due to compromised patient privacy, inadequate consent processes, and the potential misuse of genetic information. 

• High Cost of Diagnostic Tests

The high cost of advanced diagnostic tests for autoimmune diseases restricts accessibility in resource-constrained settings, hampering market growth. This financial barrier hinders widespread adoption, limiting the market's reach and preventing many individuals from undergoing crucial diagnostic procedures, contributing to a substantial gap in autoimmune disease diagnosis and management. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2023, Bayer initiated patient enrollment in its OCEANIC clinical trial program. The program assesses asundexian (BAY2433334), an oral Factor XIa inhibitor, for atrial fibrillation (AF) and non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) patients. This investigational drug aims to mitigate thrombotic risks in these conditions, potentially offering new therapeutic avenues
• In July 2022, Anthos Therapeutics' abelacimab received FDA fast-track designation for treating cancer-related thrombosis. This designation accelerates the drug's regulatory review process, recognizing its potential in addressing thrombotic complications associated with cancer treatment, highlighting a significant step towards enhancing thrombosis management in oncology patients

Thrombosis Drug Market Scope

The market is segmented on the basis of drug class, disease type, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Factor Xa Inhibitor
• Heparin
• P2Y12 Platelet Inhibitor
• Other

 Disease Type

• Pulmonary Embolism
• Atrial Fibrillation
• Deep Vein Thrombosis
• Other

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 Route of Administration

• Oral
• Parenteral

Thrombosis Drug Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drug class, disease type, route of administration, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow at the highest growth rate in the thrombosis drug market, driven by increasing awareness and rising prevalence of conditions such as deep vein thrombosis, fostering greater demand for effective treatment and drugs for deep vein thrombosis in the region.

North America is expected to dominate the thrombosis drug market due to its high prevalence of cardiovascular diseases, a substantial geriatric population, and widespread adoption of advanced technology in the region, facilitating robust growth and innovation in treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

この市場では、各国の医療設備支出の増加、市場向け各種製品のインストールベース、ライフライン曲線を使用した技術の影響、医療規制シナリオの変化と市場への影響など、詳細な市場分析も提供しています。データは、2016年から2021年までの履歴期間について利用可能です。

競争環境と血栓症治療薬の市場シェア分析

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

市場で活動している主要企業は次のとおりです。

• アストラゼネカ（英国）
• ベーリンガーインゲルハイムインターナショナルGmbH（ドイツ）
• ジョンソン・エンド・ジョンソン・サービス社（米国）
• サノフィ（フランス）
• アスペンホールディングス（南アフリカ）
• バイエルAG（ドイツ）
• ブリストル マイヤーズ スクイブ（米国）
• ファイザー社（米国）
• バクスター（米国）
• GSK plc（英国）
• 第一三共株式会社（日本）
• グリフォルス、SA（スペイン）
• ビアトリス社（米国）
• バイオジェン（米国）
• ヴァスダファーマ（インド）
• GoodRx, Inc.（米国）
• ITALFARMACO SpA (イタリア)

SKU-59730